Trials / Completed
CompletedNCT01160861
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis
A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase Ib, randomized, blinded, placebo-controlled, multiple-ascending dose study in patients with seasonal or perennial allergic rhinitis to investigate the safety, tolerability, and pharmacokinetics (PK) of MEMP1972A.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MEMP1972A | Repeating ascending dose |
| DRUG | placebo | Repeating ascending dose |
Timeline
- Start date
- 2010-07-11
- Primary completion
- 2011-04-01
- Completion
- 2011-04-01
- First posted
- 2010-07-12
- Last updated
- 2022-12-12
Source: ClinicalTrials.gov record NCT01160861. Inclusion in this directory is not an endorsement.